Open AccessAdverse events related to unapproved stem cell products and other regenerative interventions: recommendations for more robust regulation of the direct-to-consumer marketplace
Author(s) -
Farzana Akkas,
Leigh Turner,
Elizabeth Richardson
Publication year - 2022
Publication title -
regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 63
eISSN - 1746-076X
pISSN - 1746-0751
DOI - 10.2217/rme-2021-0124
Subject(s) - regenerative medicine , psychological intervention , business , adverse effect , public health interventions , public health , marketing , internet privacy , stem cell , medicine , computer science , pharmacology , psychiatry , genetics , nursing , biology
Tweetable abstract Adverse events continue to occur in the direct-to-consumer market for unapproved regenerative interventions and the US FDA alone cannot adequately address the problem. Other public health strategies are needed to provide better patient protection.